Granted Patent
B2
US 12,589,104 · App. 17/924,662 · Granted Mar 31, 2026
Thiosaccharides for use in treating coronavirus infection
Inventors:
John Vincent Fahy (San Francisco, CA); Irina Gitlin (San Francisco, CA); Wilfred Raymond (San Francisco, CA); Stefan Oscarson (Dublin, IE)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein, inter alia, are methods of using thiosaccharide compounds for treating coronavirus infection.
Claims (14)
1 . A pharmaceutical composition in the form of a liquid solution, comprising water and a thiosaccharide compound having the formula:
wherein said thiosaccharide compound is present at a concentration of about 30.0 mg/mL in the pharmaceutical composition.
2 . The pharmaceutical composition of claim 1 , further comprising sodium citrate.
3 . The pharmaceutical composition of claim 1 , further comprising sodium chloride.
4 . The pharmaceutical composition of claim 2 , further comprising sodium chloride.
5 . The pharmaceutical composition of claim 1 , wherein said thiosaccharide compound is present at a concentration of 30.0 mg/mL in the pharmaceutical composition.
6 . The pharmaceutical composition of claim 2 , wherein said thiosaccharide compound is present at a concentration of 30.0 mg/mL in the pharmaceutical composition.
7 . The pharmaceutical composition of claim 3 , wherein said thiosaccharide compound is present at a concentration of 30.0 mg/mL in the pharmaceutical composition.
8 . The pharmaceutical composition of claim 4 , wherein said thiosaccharide compound is present at a concentration of 30.0 mg/mL in the pharmaceutical composition.
9 . A pharmaceutical composition in the form of a liquid solution, comprising water and a thiosaccharide compound having the formula:
wherein said thiosaccharide compound is present at a concentration of 30.0 mg/mL or higher in the pharmaceutical composition.
10 . The pharmaceutical composition of claim 9 , further comprising sodium citrate.
11 . The pharmaceutical composition of claim 9 , further comprising sodium chloride.
12 . The pharmaceutical composition of claim 10 , further comprising sodium chloride.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 2, 2023
From: OSCARSON, STEFAN
To: UNIVERSITY COLLEGE DUBLIN
Reel/Frame 062569/0147 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 2, 2023
From: FAHY, JOHN V.; GITLIN, IRINA; RAYMOND, WILFRED W.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 062569/0189 →
Continuity (2)
Provisional Application
63024107
· May 13, 2020
References Cited (52)
US 9856283B2
· Oscarson
· 2018
[cited by examiner]
US 9963427B2
· Johnson et al.
· 2018
[cited by applicant]
US 20090068142A1
· Blatt
· 2009
[cited by applicant]
US 20090156473A1
· Schubert
· 2009
[cited by applicant]
US 20110218241A1
· Preston et al.
· 2011
[cited by applicant]
US 20180344751A1
· Walker et al.
· 2018
[cited by applicant]
US 20230172885A1
· Fahy et al.
· 2023
[cited by applicant]
US 20230285441A1
· Kumar
· 2023
[cited by examiner]
WO WO2017197360A1
· 2017
[cited by applicant]
WO WO2020055916A1
· 2020
[cited by applicant]
WO WO2021217221A1
· 2021
[cited by applicant]
WO WO2021231421A1
· 2021
[cited by applicant]
Brady, Bernadette et al., Carbohydrate Research, “Bisthiocyclomalto-oligosaccharides with trehalosyl and octyl links: their synthesis for dual-cavity inclusion”, 1998, vol. 309, pp. 237-241 (Year: 1998).
[cited by examiner]
Khanna, K. et al. (Dec. 8, 2020). “Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence from in vitro SARS-CoV-2 infection studies,”
[cited by applicant]
Khanna, K. et al. (Nov. 11, 2021). “Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro,”
[cited by applicant]
Partial European Search Report mailed on May 10, 2024, for EP Patent Application No. 21802893.4, 18 pages.
[cited by applicant]
Rothan, H. A. et al. (Aug. 2020). “The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-CoV-2) replication and attenuates inflammation in human cells,”
[cited by applicant]
Shi, Y. et al. (Feb. 8, 2022). “Thiol-based chemical probes exhibit antiviral activity against SARS-CoV-2 via allosteric disulfide disruption in the spike glycoprotein,”
[cited by applicant]
Abell, B.A. et al. (Sep. 1993). “Sindbis virus membrane fusion is mediated by reduction of glycoprotein disulfide bridges at the cell surface,”
[cited by applicant]
Akerlund, B. et al. (1996). “Effect of N-acetylcysteine(NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial,”
[cited by applicant]
Ali, F. et al. (Jun. 2021, e-published Mar. 2, 2021). “The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant,”
[cited by applicant]
Bouazza, N. et al. (Dec. 2011). “Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients,”
[cited by applicant]
Chan, J. F. W. et al. (Dec. 3, 2020). “Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transm…
[cited by applicant]
Gallagher, T.M. (Jul. 1996). “Murine coronavirus membrane fusion is blocked by modification of thiols buried within the spike protein,”
[cited by applicant]
Gallina, A. et al. (Dec. 27, 2002). “Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry,”
[cited by applicant]
Hati, S. et al. (Jun. 23, 2020). “Impact of Thiol-Disulfide Balance on the Binding of Covid-19 Spike Protein with Angiotensin-Converting Enzyme 2 Receptor,”
[cited by applicant]
Horowitz, R.I. et al. (Apr. 21, 2020). “Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases,”
[cited by applicant]
Imai, M. et al. (Jul. 14, 2020, e-published Jun. 22, 2020). “Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development,”
[cited by applicant]
International Search Report mailed on Sep. 8, 2021, for PCT Application PCT/US2021/031772, filed May 11, 2021, 2 pages.
[cited by applicant]
International Search Report mailed on Sep. 8, 2021, for PCT Application PCT/US2021/031734, filed May 11, 2021, 3 pages.
[cited by applicant]
Lan, J. et al. (May 2020). “Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor,”
[cited by applicant]
Lavillette, D. et al. (Apr. 7, 2006, e-published Jan. 17, 2006). “Significant redox insensitivity of the functions of the SARS-CoV spike glycoprotein: comparison with HIV envelope,”
[cited by applicant]
Lobo-Galo, N. et al. (Jun. 2021). “FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication,”
[cited by applicant]
Luan, B. et al. (Mar. 17, 2021). “Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations,”
[cited by applicant]
Roberts, A. et al. (Jan. 2005). “Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters,”
[cited by applicant]
Ryser, H.J. et al. (May 10, 1994). “Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction,”
[cited by applicant]
Sia, S. F. et al. (Jul. 2020, e-published May 14, 2020). “Pathogenesis and transmission of SARS-CoV-2 in golden hamsters,”
[cited by applicant]
Tian, F. et al. (2021). “Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2,”
[cited by applicant]
Wallin, M. et al. (Jan. 14, 2004, e-published Dec. 11, 2003). “Isomerization of the intersubunit disulphide-bond in Env controls retrovirus fusion,”
[cited by applicant]
Wang, Q. et al. (May 14, 2020, e-published Apr. 9, 2020). “Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2,”
[cited by applicant]
Whitt, M.A. (Nov. 2010, e-published Aug. 13, 2010). “Generation of VSV pseudotypes using recombinant AG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines,”
[cited by applicant]
Wong, S.K. et al. (Jan. 30, 2004, e-published Dec. 11, 2003). “A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2,”
[cited by applicant]
Written Opinion mailed on Sep. 8, 2021, for PCT Application PCT/US2021/031772, filed May 11, 2021, 6 pages.
[cited by applicant]
Written Opinion mailed on Sep. 8, 2021, for PCT Application PCT/US2021/031734, filed May 11, 2021, 9 pages.
[cited by applicant]
Yuan, S. et al. (Feb. 25, 2015). “Oxidation increases mucin polymer cross-links to stiffen airway mucus gels,”
[cited by applicant]
Extended European Search Report mailed on Apr. 18, 2024, for EP Patent Application No. 21804356.0, 9 pages.
[cited by applicant]